Christopher J Poole

Christopher J Poole

Auto-generated profile, based on publicly available information

Christopher J Poole

The University of Birmingham, Birmingham West, Midlands, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Addenbrooke's Hospital, University of Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2006 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
CPChristopher J Poole
Christopher J Poole
HEHelena M Earl
Helena M Earl
LHLouise Hiller
Louise Hiller
JDJanet A Dunn
Janet A Dunn
SBSarah Bathers
Sarah Bathers
CTChristopher J Twelves
Christopher J Twelves
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer.

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RGR. G. Gray
R. G. Gray
DRD. W. Rea
D. W. Rea
KHK. Handley
K. Handley
AMA. Marshall
A. Marshall
MPM. G. Pritchard
M. G. Pritchard
ACAttom Collaborators
Attom Collaborators
513 Background: In ER+ early breast cancer, 5 years of tamoxifen substantially reduces the annual recurrence rate throughout the first decade (years 0–9). Despite this, appreciable risks of recurrence remain, with similar annual recurrence risks for ER+ disease during years 0–4, 5–9 and 10–14 following surgery. It is not reliably known how 10 years duration of adjuvant tamoxifen compares with the current standard of 5 years. Methods: Between 1991 and 2005, 6,934 women with ER+ (39%), or ER untested (61%) invasive breast cancer (53% node negative, 31% node positive, 16% node status unspecified) from 176 UK centers, who had completed 4+ years of adjuvant tamoxifen, were randomized between continuing for another 5 years and stopping. Information on compliance, hospital admission(s), breast cancer recurrence (including new contralateral disease), other new primary cancer, death and cause of death was sought annually. Results: 78% of those allocated to continue and 3% of those allocated to stop were taking adjuvant tamoxifen at 3 years following randomization; fewer than 1% switched to any other adjuvant hormone treatment. With a median follow-up of 4.2 years, there were fewer recurrences (415 vs 442; RR=0.94, 95% CI 0.81–1.09; p=0.4) among those allocated to 10yrs than 5yrs tamoxifen. Although breast cancer mortality was lower among those allocated 10yrs, with just 374 deaths from breast cancer recorded, data remain immature. Despite a doubling in the risk of endometrial cancer (76 vs 35) with 10yrs tamoxifen, there was no increase in deaths from endometrial cancer (10 vs 12) or from any other non-breast cancer cause. Conclusions: Although no significant reduction in recurrence has yet been seen in aTTom, the results are consistent with preliminary findings from the ATLAS trial, which reported a DFS but not overall survival advantage to longer tamoxifen (Peto et al SABCS 2007). Combining results from these two large studies indicate that continuation of tamoxifen beyond the first 5 years reduces recurrence over the next few years, but further follow-up is needed to assess reliably the longer-term effects on recurrence and the net effects, if any, on mortality. No significant financial relationships to disclose.

20 May 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CPC. J. Poole
C. J. Poole
LHLouise Hiller
Louise Hiller
HHH. C. Howard
H. C. Howard
JDJ. A. Dunn
J. A. Dunn
PCP. Canney
P. Canney
TCtAnGo trial collaborators
tAnGo trial collaborators
506 Background: After gem showed encouraging activity in advanced BC and pre-clinical evidence of a favorable interaction with paclitaxel, tAnGo was designed to evaluate, for the first time, its potential role in anthracycline and taxane containing adjuvant CT for EBC. Methods: tAnGo, an international phase III trial, compared EC-GT (4 cycles of epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV day1 every (q) 3 weeks, followed by 4 cycles of paclitaxel 175mg/m2/3hour infusion day1 and gem 1,250mg/m2 IV days1 and 8 q3 weeks) with EC-T, in respect of disease-free survival (DFS) in women with invasive higher risk EBC, with definite indication for adjuvant CT. Stratification was by country, age, radiotherapy, and nodal, estrogen (ER) & HER2 status. Toxicity, dose delivery and QoL, presented at ASCO'04 and SABCS'06, showed both regimens to be safe, feasible and tolerable. We anticipated 550 DFS events at the preplanned primary endpoint efficacy analysis at 30 months (m) minimum follow-up (FU). Results: Between Aug'01-Nov'04, 3,152 patients were randomized from UK and Ireland, by 175 consultants from 127 centers; 1,576 EC-GT, 1,576 EC-T. Characteristics were balanced across treatments: 77% node positive (+ve), 55% <50 years old, 65% of tumors grade 3, 61% >2cm, 41% ER -ve, 37% PgR -ve, 26% HER2 +ve (of 909 tumors assayed). This preplanned analysis with median FU of 35m (IQR 25–38m) identified 339 deaths and 548 DFS events. No significant difference between treatments is observed in DFS (HR=1.0 [95%CI 0.8–1.2] p=0.96) or overall survival (HR=1.1 [95%CI 0.9–1.4] p=0.35). Forest plots highlighted no subset where EC-GT was more effective, including a preplanned analysis by ER/PgR. Conclusions: The addition of gem at this dose and schedule confers no therapeutic advantage over EC-T for EBC.

15 July 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CPC. J. Poole
C. J. Poole
HHH. C. Howard
H. C. Howard
LHLouise Hiller
Louise Hiller
JDJ. A. Dunn
J. A. Dunn
AWA. M. Wardley
A. M. Wardley
HEH. M. Earl
H. M. Earl
821 Background: tAnGo is an ongoing 3000-patient (pt) randomized trial evaluating for the first time the role of G in adjuvant CT for breast cancer. We present the results of a preliminary prospective safety study designed to assess the incidence of any treatment (trt)-related clinical or sub-clinical disturbances of pulmonary, cardiac, or hepatic fn in the first 135 pts randomised. Methods: Pulmonary (Hb-adjusted TLCO, FEV1, FVC, CXR), cardiac (LVEF, ECG), and hepatic (AST/ALT) fn tests were conducted in 135 pts (66 EC+T, 69 EC+GT) at baseline, mid-CT, post-CT/pre-RT, and 6 months post-CT. Results: Pulmonary fn tests: majority normal at all time points, with no differences between trts or changes over time in FEV1 (p>0.3 and 0.9 resp) or FVC (p=0.95 and 0.5 resp). TLCO dropped marginally during trt (p0.25) and no changes over time (p=0.14). Cardiac fn tests: 95% of all Echo/MUGA scans and 90% of all ECGs normal, with no differences between trts (p>0.35 and >0.25 resp) and no changes in Echo/MUGAs over time (p=0.4); only a slight time effect in ECGs (p=0.03). Hepatic fn tests: 92% of all AST levels and 82% of all ALT levels normal (majority of abnormal results graded 1/2): EC+T pts show a modest increase in transaminases at mid-CT but this resolves by post-CT (AST p=0.08 and ALT p=0.38 for change over time); transaminase increases in EC+GT pts persist post-CT but resolve by 6 months (AST p=0.004 and ALT p=0.001 resp for change over time). Acute skin toxicity during RT: 87% of reports graded this as Nil/Mild; only 1% as severe; no difference between trts (p>0.1), although severity increased over time (p<0.0001). There were no trt related deaths. Conclusions: These data suggest that clinically relevant trt effects on pulmonary or cardiac fn will be rare over the course of the entire study. Reported transaminase increases are both modest and reversible. Long term follow-up tests will be performed at 5 and 10 yrs. No significant financial relationships to disclose.

1 December 2000 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
CPC. J. Poole
C. J. Poole
TPT. Perren
T. Perren
ABA. Burton
A. Burton
SJS. D. Jordan
S. D. Jordan
AJA. H. Jenkins
A. H. Jenkins
HEH. M. Earl
H. M. Earl
Purpose: To examine the activity and safety of two sequentially scheduled chemotherapy regimens comprising four cycles of paclitaxel (pctx) 200 mg/m2/3 hours then four cycles of cisplatin (cisDDP) 100 mg/m2, and vice versa, in patients with previously untreated advanced ovarian cancer.Patients and methods: Between January 1994 and February 1996, we recruited 30 patients to the pctx-then-cisDDP regimen and 29 to cisDDP-then-pctx, in parallel phase II trials.Results: Both regimens were predictably active with responses seen in 22 of 30 patients (OR 74% CR 27%, PR 47%) treated with pctx-then-cisDDP, as against 13 of 21 patients (OR 62% CR 38% PR 24%) treated with cisDDP-then-pctx, The OR rate to four cycles of pctx (induction) was 43%, with 27% disease progression; the OR to four cycles of cisDDP (induction) was 57%, with 5% progression. However, progression rates across both induction and consolidation phases were 16% (pctx-then-cisDDP) and 29% (cisDDP-then-pctx). Both regimens were unacceptably neurotoxic, 11 patients suffering grade 3 sensory neurotoxicity (5 on pctx-then-cisDDP, 6 on cisDDP-then-pctx) and 20 having grade 3 deafness (9 on pctx-then-cisDDP, 11 on cisDDP-then-pctx).Conclusion: The activity of these sequential regimens justifies their further development using the less neurotoxic platinum analogue carboplatin, perhaps combining paclitaxel with other platinum non-cross resistant drugs.